Biomarker compositions, protein panels, devices, and methods to identify risk of and treat pulmonary vascular inadequacy in single ventricle heart disease
AssigneeThe Regents of the University of Colorado, a body corporate
InventorsBenjamin Frank, Jesse Davidson
Life of this patent
Estimating the term…
Abstract
Disclosed herein are methods, compositions and devices for diagnosing pathologic pulmonary vascular disease development, progression, and outcomes from cardiac surgical interventions, particularly surgical palliation in SVHD, and more particularly superior cavopulmonary anastomosis procedures. In particular, methods are provided for assessing risk of post-Stage 2 complications arising from intolerance of Stage 2 physiology due to e.g., pulmonary vascular inadequacy.
Claims20
A method of assessing risk of a morbidity to surgical palliation in a subject having single-ventricle heart disease (SVHD), comprising:
- obtaining a sample of circulating proteins from the subject prior to the surgical palliation;
- testing the sample to determine a level of one or more protein biomarkers selected from the group consisting of matrix metalloproteinase (MMP), tissue inhibitor of metalloproteinase (TIMP), and fibroblast growth factor (FGF);
- comparing the level to a reference range for the one or more protein biomarkers;
- and
- identifying the subject as being at risk for the morbidity where the level is outside the reference range.
A composition for diagnosing pulmonary vascular inadequacy in a subject having single-ventricle heart disease (SVHD), comprising at least one molecule having affinity for a biomarker, wherein the biomarker is a protein selected from group consisting of matrix metalloproteinase (MMP), tissue inhibitor of metalloproteinase (TIMP), and fibroblast growth factor (FGF).
Dependencies are inferred from the claim text.